BIM and SHP2 expression levels to predict clinical outcome to EGFR tyrosine kinase inhibitors (TKI) in EGFR-mutant non-small-cell lung cancer (NSCLC) patients (p).

Egfr Mutant ◽

Nsclc Patients

Targeting Resistance in Egfr-Mutant Non-Small Cell Lung Cancer (Nsclc): Preclinical Evidence Supporting the Combination of Egfr Tyrosine Kinase Inhibitors (Tkis) Azd9291 and Gefitinib with Molecularly Targeted Agents and Immunotherapeutics

Annals of Oncology ◽

10.1093/annonc/mdu331.26 ◽

2014 ◽

Vol 25 ◽

pp. iv155 ◽

Cited By ~ 1

Author(s):

D. Cross ◽

C. D'Cruz ◽

C. Eberlein ◽

P. Spitzler ◽

E. Ichihara ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Targeted Agents ◽

Small Cell Lung ◽

Molecularly Targeted Agents ◽

Clinical Outcome of ALK -Positive Non–Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs)

Journal of Thoracic Oncology ◽

10.1016/j.jtho.2016.12.003 ◽

2017 ◽

Vol 12 (4) ◽

pp. 681-688 ◽

Cited By ~ 22

Author(s):

Sabine Schmid ◽

Oliver Gautschi ◽

Sacha Rothschild ◽

Michael Mark ◽

Patrizia Froesch ◽

...

Keyword(s):

Lung Cancer ◽

Clinical Outcome ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

De Novo ◽

Small Cell ◽

Small Cell Lung ◽

Alk Positive ◽

Nsclc Patients

Clinical Predictors of Response to EGFR Tyrosine Kinase Inhibitors in Patients with EGFR-Mutant Non-Small Cell Lung Cancer

Oncology ◽

10.1159/000357129 ◽

2014 ◽

Vol 86 (2) ◽

pp. 86-93 ◽

Cited By ~ 10

Author(s):

Jun Fukihara ◽

Naohiro Watanabe ◽

Hiroyuki Taniguchi ◽

Yasuhiro Kondoh ◽

Tomoki Kimura ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Small Cell Lung ◽

Clinical Predictors ◽

Predictors Of Response ◽

Comparison of the Efficacy of EGFR Tyrosine Kinase Inhibitors Erlotinib and Low-dose Osimertinib on a PC-9-GFP EGFR Mutant Non-small-cell Lung Cancer Growing in the Brain of Nude Mice

In Vivo ◽

10.21873/invivo.11871 ◽

2020 ◽

Vol 34 (3) ◽

pp. 1027-1030

Author(s):

YUKI KATSUYA ◽

KENTARO MIYAKE ◽

TAKASHI HIGUCHI ◽

HIROMICHI OSHIRO ◽

NORIHIKO SUGISAWA ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Low Dose ◽

Kinase Inhibitors ◽

Small Cell ◽

Small Cell Lung ◽

Egfr Mutant ◽

The Brain

Afatinib (Afa) plus bevacizumab (Bev) combination after acquired resistance (AR) to EGFR-tyrosine kinase inhibitors (TKIs) in EGFR-mutant non-small cell lung cancer (NSCLC): Multicenter single arm phase II trial (ABC-study)

Annals of Oncology ◽

10.1093/annonc/mdx671.012 ◽

2017 ◽

Vol 28 ◽

pp. x129

Author(s):

M. Tamiya ◽

A. Hata ◽

N. Katakami ◽

R. Kaji ◽

T. Yokoyama ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Phase Ii Trial ◽

Acquired Resistance ◽

Small Cell ◽

Small Cell Lung ◽

Adjuvant EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer: still an investigational approach

Translational Lung Cancer Research ◽

10.21037/tlcr.2019.09.02 ◽

2019 ◽

Vol 8 (S4) ◽

pp. S387-S390

Author(s):

Jacek Jassem

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Small Cell Lung ◽

The BIM Deletion Polymorphism and its Clinical Implication in Patients with EGFR-Mutant Non–Small-Cell Lung Cancer Treated with EGFR Tyrosine Kinase Inhibitors

Journal of Thoracic Oncology ◽

10.1097/jto.0000000000000535 ◽

2015 ◽

Vol 10 (6) ◽

pp. 903-909 ◽

Cited By ~ 19

Author(s):

Ji Yun Lee ◽

Bo Mi Ku ◽

Sung Hee Lim ◽

Min-Young Lee ◽

Haesu Kim ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Clinical Implication ◽

Kinase Inhibitors ◽

Small Cell ◽

Small Cell Lung ◽

Deletion Polymorphism ◽

Mimicking the BIM BH3 domain overcomes resistance to EGFR tyrosine kinase inhibitors in EGFR-mutant non-small cell lung cancer

Oncotarget ◽

10.18632/oncotarget.19411 ◽

2017 ◽

Vol 8 (65) ◽

pp. 108522-108533 ◽

Cited By ~ 4

Author(s):

Jinjing Xia ◽

Hao Bai ◽

Bo Yan ◽

Rong Li ◽

Minhua Shao ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Small Cell ◽

Small Cell Lung ◽

Bh3 Domain ◽

Feasibility of rebiopsy and sequential treatment of EGFR tyrosine kinase inhibitors in real world patients with EGFR mutant non-small cell lung cancer

Annals of Oncology ◽

10.1093/annonc/mdz437.018 ◽

2019 ◽

Vol 30 ◽

pp. ix166

Author(s):

H. Ahn ◽

Y. Kim ◽

E.Y. Kim ◽

K.W. Kim ◽

K.H. Sung ◽

...

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Real World ◽

Kinase Inhibitors ◽

Small Cell ◽

Small Cell Lung ◽

Use of adjuvant EGFR tyrosine kinase inhibitors in early stage EGFR-mutant non-small cell lung cancer: is the evidence strong enough?

Journal of Thoracic Disease ◽

10.21037/jtd-20-1817 ◽

2020 ◽

Vol 12 (9) ◽

pp. 5042-5045

Author(s):

Christopher Lemmon ◽

Nathan A. Pennell

Keyword(s):

Lung Cancer ◽

Tyrosine Kinase ◽

Small Cell Lung Cancer ◽

Kinase Inhibitors ◽

Early Stage ◽

Small Cell ◽

Small Cell Lung ◽